©2021-2032 All Rights Reserved. Online Journal of Bioinformatics. You may not store these pages in any form except
for your own personal use. All other usage or distribution is illegal under
international copyright treaties. Permission to use any of these pages in any
other way besides the
before mentioned must be gained in writing from the publisher. This article is
exclusively copyrighted in its entirety to onlinejournals@gmail.com
publications. This article may be copied once but may not be, reproduced or re-transmitted
without the express permission of the editors. Linking: To link to this page or
any pages linking to this page you must link directly to this page only here
rather than put up your own page.
OJBTM
Online Journal of
Bioinformatics©
Established 1995
ISSN 1443-2250
Volume 23 (3):287-297, 2022.
In silico binding
dipeptidyl peptidase target protein for diabetes mellitus 2.
Rajeev Sharmah, Subrata Sinha, Surabhi Johari
Center for Bioinformatics Studies,
Department of Life sciences, Dibrugarh University, Dibrugarh Assam, India.
ABSTRACT
Sharmah R, Sinha
S, Johari S., In
silico binding dipeptidyl peptidase target protein for diabetes mellitus 2, Onl J Bioinform., 23 (3):287-297, 2022.
Diabetes mellitus type 2 is caused by lack of insulin production. Di-peptidyl peptidase IV (DPP IV) protease degrades
incretins that stimulate secretion of insulin so its inhibition should boost
insulin. We retrieved sequence DPP IV for In silico docking. We designed
drug using methylamine as lead molecule. Results from OSIRIS and MOLINSPIRATION
show the methyl amines with drug score of 0.83. The drug (3-[3-(methyl amino) cyclopentyl] pentane-1, 2-diol) was non-mutagenic, irritant,
tumerogenic or reproductive effects with low
molecular weight drug.
Key-words: Diabetes,
Glucagon like peptide, Dipeptidyl Peptidase IV, Drug.
FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE)